NOXA has been proven as a particularly relevant therapeutic target for several tumors, such as chronic lymphocytic leukemia (CLL) [21, 22], liver cancer [23], lung cancer [24] and ESCC [25]. This evidence concerns the gene PMAIP1 and B-cell chronic lymphocytic leukemia.